Insight

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Photo from Umang Swami/X

Aug 5, 2024, 02:38

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Umang Swami, Oncologist at Huntsman Cancer Institute, University of Utah, shared a post on X about a recent paper titled “Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States” published in Future Oncology.

Authors: Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar and Sumati Gupta.

“Just in Future Oncology. One of the largest real world studies evaluating TRT trends in nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common TRT.”

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Source: Umang Swami/X

ADT ADT+NSAA Agnes Hong Benjamin Chastek Bin Xie Brandon Diessner cancer Christopher Young Future Oncology Huntsman Cancer Institute Krishnan Ramaswamy Nader El Chaar NHT nmCRPC nonmetastatic castration-resistant prostate cancer OncoDaily Oncology Scott H Bunner Sumati Gupta TRT Umang Swami University of Utah

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage